IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
IGC Pharma, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.24−0.00 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $24.28M
- P/E (TTM)
- –
- Dividend yield
- –
IGC Pharma, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White Labeling Services [Member] | $256.00K | $294.00K | $335.00K | $153.00K | $322.00K | $318.00K | $223.00K | $366.00K | $251.00K | – | $157.00K | $222.00K | 96.6% | -20.5% |
| Wellness and Lifestyle [Member] | $9.00K | $23.00K | $15.00K | $38.00K | $6.00K | $12.00K | $34.00K | $46.00K | $21.00K | $63.00K | $47.00K | $69.00K | 3.4% | +50.0% |
| Legacy Infrastructure [Member] | – | – | – | – | – | – | $0 | $0 | $0 | $3.00K | $0 | $0 | – | – |
| Infrastructure Segment [Member] | – | – | – | – | – | $164.00K | $0 | $0 | $0 | – | $0 | $0 | – | – |
| Life Sciences Segment [Member] | – | – | – | – | – | $330.00K | – | – | – | – | – | – | – | – |
By region
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | $317.00K | $350.00K | $191.00K | $328.00K | $330.00K | $257.00K | $410.00K | $272.00K | $290.00K | $204.00K | $291.00K | – | – |
| India | – | – | – | – | $0 | – | – | $0 | $0 | $3.00K | $0 | $0 | – | – |
| Colombia | – | – | $0 | $0 | $0 | $0 | $0 | $2.00K | $0 | – | – | – | – | – |
From the segment and revenue-disaggregation notes of IGC Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.